AIDS Res Hum Retroviruses by Koethe, John R. et al.
Rising Obesity Prevalence and Weight Gain Among Adults 
Starting Antiretroviral Therapy in the United States and Canada
John R. Koethe1, Cathy A. Jenkins1, Bryan Lau2, Bryan E. Shepherd1, Amy C. Justice3,4, 
Janet P. Tate3,4, Kate Buchacz5, Sonia Napravnik6, Angel M. Mayor7, Michael A. Horberg8, 
Aaron J. Blashill9, Amanda Willig10, C. William Wester1, Michael J. Silverberg11, John 
Gill12, Jennifer E. Thorne2, Marina Klein13, Joseph J. Eron6, Mari M. Kitahata14, Timothy R. 
Sterling1, Richard D. Moore2, and for the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD)
1Vanderbilt University School of Medicine, Nashville, Tennessee 2Johns Hopkins University, 
Baltimore, Maryland 3Yale School of Medicine, New Haven, Connecticut 4VA Connecticut 
Healthcare System, West Haven, Connecticut 5Division of HIV/AIDS Prevention, Centers for 
Disease Control and Prevention, Atlanta, Georgia 6University of North Carolina, Chapel Hill, North 
Carolina 7Universidad Central del Caribe, Bayamon, Puerto Rico 8Mid-Atlantic Permanente 
Research Institute, Rockville, Maryland 9Harvard Medical School, Boston, Massachusetts 
10University of Alabama at Birmingham, Birmingham, Alabama 11Kaiser Permanente Northern 
California, Oakland, California 12Alberta HIV Clinic, Sheldon M. Chumir Health Centre, Calgary, 
Alberta, Canada 13McGill University Health Center, Montreal, Quebec, Canada 14University of 
Washington, Seattle, Washington
Abstract
The proportion of overweight and obese adults in the United States and Canada has increased over 
the past decade, but temporal trends in body mass index (BMI) and weight gain on antiretroviral 
therapy (ART) among HIV-infected adults have not been well characterized. We conducted a 
cohort study comparing HIV-infected adults in the North America AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) to United States National Health and Nutrition Examination 
Survey (NHANES) controls matched by sex, race, and age over the period 1998 to 2010. 
Multivariable linear regression assessed the relationship between BMI and year of ART initiation, 
adjusting for sex, race, age, and baseline CD4+ count. Temporal trends in weight on ART were 
assessed using a generalized least-squares model further adjusted for HIV-1 RNA and first ART 
regimen class. A total of 14,084 patients from 17 cohorts contributed data; 83% were male, 57% 
were nonwhite, and the median age was 40 years. Median BMI at ART initiation increased from 
23.8 to 24.8 kg/m2 between 1998 and 2010 in NA-ACCORD, but the percentage of those obese 
(BMI ≥30 kg/m2) at ART initiation increased from 9% to 18%. After 3 years of ART, 22% of 
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individuals with a normal BMI (18.5–24.9 kg/m2) at baseline had become overweight (BMI 25.0–
29.9 kg/m2), and 18% of those overweight at baseline had become obese. HIV-infected white 
women had a higher BMI after 3 years of ART as compared to age-matched white women in 
NHANES (p = 0.02), while no difference in BMI after 3 years of ART was observed for HIV-
infected men or non-white women compared to controls. The high prevalence of obesity we 
observed among ART-exposed HIV-infected adults in North America may contribute to health 
complications in the future.
Introduction
The proportion of overweight and obese individuals in the general population of the United 
States and Canada has increased steadily over the past three decades, affecting all race/
ethnicity, sex, and age groups to varying degrees.1,2 Over one-third of adults in the United 
States are overweight [body mass index (BMI) 25–29.9 kg/m2] and a similar proportion is 
obese (BMI ≥30 kg/m2), while in Canada over one-third are overweight and one-quarter are 
obese.1,3 Prior studies from single HIV cohorts or clinics in the United States have reported 
overweight and obesity prevalence rates comparable to the national average, and higher 
among minorities and women (a finding also observed in the general population).4–7 
However, these studies may reflect local dietary and physical activity patterns, and there 
have been no analyses to date of sex, race/ethnicity, and temporal trends in BMI and weight 
gain on antiretroviral therapy (ART) in HIV-infected individuals across multiple, 
geographically disparate cohorts in North America.
In the pre-ART era, prevention of HIV-associated wasting and the promotion of weight gain 
were viewed as beneficial, but in the era of effective ART, there is evidence that being 
overweight or obese may increase the risk of several co-morbidities accompanying long-
term HIV treatment.8–10 In a recent single-site study at an HIV clinic with a high proportion 
of obese patients the prevalence of “multimorbidity” (i.e., more than one comorbid chronic 
illness) increased in a stepwise fashion with BMI strata.8 Studies of the general population 
show that longitudinal increases in weight are associated with detrimental changes in 
cardiovascular and metabolic parameters, including blood pressure, dyslipidemia, markers 
of systemic inflammation, and insulin resistance.11–14
Characterizing the intersection of the obesity and HIV epidemics is important for situating 
nutritional counseling and primary disease prevention in the context of longitudinal HIV 
clinical care. We hypothesized that the BMI of HIV-infected adults starting ART in the 
United States and Canada rose over the first decade of the twenty-first century, just as the 
mean BMI of the general population increased, and that HIV-infected adults in all BMI 
categories gained weight after treatment initiation. In this analysis, we assessed temporal, 
sex, and race differences in BMI at the time of ART initiation and weight change on 
treatment among adults enrolled in the North American AIDS Cohort Collaboration on 
Research and Design (NA-ACCORD) over the period 1998–2010. Furthermore, we 
compared the pretreatment and on-ART BMI values of NA-ACCORD patients with 
National Health and Nutrition Examination Survey (NHANES) participants matched by age, 
race, and sex over corresponding calendar periods.
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NA-ACCORD is a multisite collaboration involving 25 cohort studies representing over 100 
clinical and research sites for HIV-infected persons in the United States and Canada, and it 
is one of the regional cohort study groups supported by the International Epidemiologic 
Databases to Evaluate AIDS (IeDEA) consortium of the National Institutes of Health.15 NA-
ACCORD collects standardized data on demographic characteristics, antiretroviral 
medication use, laboratory values, clinical diagnoses, and vital status. Data are transmitted 
to a centralized core at regular intervals for quality control and harmonization. Institutional 
review boards at each participating site have reviewed and approved the activities of NA-
ACCORD.
We assessed the relationships between BMI at ART initiation, and weight change after 1 and 
3 years on treatment, among ART-naive adults starting a first antiretroviral regimen (defined 
as three or more medications) from 1998 to 2010 in NA-ACCORD. Seventeen of the 25 
NA-ACCORD cohorts reported longitudinal BMI data, which included clinical sites in 28 
states in all regions of the United States, the District of Columbia, and in Quebec, Ontario, 
and the Maritime Provinces in Canada. Because NA-ACCORD lacks information on 
pregnancy among female participants, we excluded women with more than a 10% weight 
change within 6 months of starting ART from the analysis cohort (n = 1134).
To be included in the analysis of BMI at ART initiation, NA-ACCORD participants had to 
have at least one weight value within 180 days before to 30 days after the start date of the 
first regimen (the value closest to this date was selected); there were no restrictions on when 
height, used to calculate BMI, was recorded. To be included in the longitudinal analyses of 
weight change, participants had to have at least one weight measurement more than 30 days 
after ART initiation, which was available in 96% of those with a baseline weight. Weight at 
1 year was the value closest to 12 months of ART but prior to 1.5 years of follow-up, while 
weight at 3 years was the value closest to 36 months of ART, within a window period 
between 2.5 and 3.5 years of follow-up. Participants who died or were lost to follow-up 
prior to 2.5 years of ART were censored for the 3-year analyses. BMI was treated as a 
continuous variable in the linear models, but, for the purpose of comparing groups, BMI was 
categorized according to standard convention as underweight (<18.5 kg/m2), normal (18.5–
24.9 kg/m2), overweight (25–29.9 kg/m2), obese (30–40 kg/m2), and morbidly obese (>40 
kg/m2).16 Baseline CD4+ T cell count was also the closest value to the start date within 180 
days before to 30 days after, while plasma HIV-1 RNA was the closest value within 180 
days prior to the start of ART.
The relationship between BMI and year of ART initiation was assessed using a linear model 
adjusted for sex, race (white, nonwhite, and unknown), age, baseline CD4+ T cell count, and 
cohort. To avoid assuming a linear relationship, continuous covariates were modeled using 
restricted cubic splines with four knots.17 We included an interaction term for sex and BMI, 
and race and BMI, given differences reported in the general population.1 The estimated BMI 
at ART initiation between 1998 and 2010, stratified by sex and by race, was extracted from 
the model and displayed graphically. For comparison, we calculated sex- and race-stratified 
BMI estimates for the general U.S. population between 1998 and 2010 using NHANES data 
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(reported in 2-year intervals) appropriately weighted according to CDC guidelines to 
account for the sampling design.18 The NHANES estimates were then weighted to match the 
age distribution of NA-ACCORD participants. The mean number of NHANES respondents 
per 2-year cohort between 1998 and 2010 was 9,815.
To assess whether the average weight gain after starting ART differed according to sex and 
race, or changed between 1998 and 2010, we modeled time varying weight after ART 
initiation (up to 3 years of follow-up) using a generalized least-squares model to account for 
the within-subject correlation induced by repeated measures on a subject. We chose to report 
the results from the analysis using weight rather than BMI because weight is more 
commonly used in clinical practice. The model used weight over time on ART as the 
outcome, adjusting for time of weight measurement since ART initiation, age, sex, race, 
cohort, year of ART initiation, the initial ART regimen [classified as nonnucleoside reverse 
transcriptase inhibitor (NNRTI) based, protease inhibitor (PI) based, nucleoside reverse 
transcriptase inhibitors (NRTI) only, or “other”], and baseline weight, CD4 count, and log10 
viral load. The model also included interaction terms between year of ART initiation and 
time, between sex and time, and between race and time. To avoid assuming a linear 
relationship between the continuous covariates and the outcome, weight, CD4 count, viral 
load, age, and year at ART initiation were modeled using restricted cubic splines with four 
knots. Participants were censored at the time of a recorded ART discontinuation. Missing 
baseline viral loads (3%) were singly imputed with the median of the nonmissing values.
Because the criteria for identifying potential pregnancies were imprecise, two sensitivity 
analyses excluding all women under 35 years of age and under 40 years of age were 
performed for the time-varying analyses.
Results
Data on 14,084 HIV-infected, ART-naive individuals who started treatment from 1998 
through 2010 and had a baseline BMI value recorded were available from 17 cohorts in NA-
ACCORD (Table 1). The racial/ethnic distribution was 43% non-Hispanic white, 38% non-
Hispanic black, 15% Hispanic, 4% other, and 1% unknown. Higher BMI participants were 
more likely to be female, nonwhite, have a higher pretreatment CD4+ T cell count, start 
ART in a later calendar year, and have a lower pretreatment log10 viral load (p < 0.01 for 
all). While the percentage of underweight individuals (BMI <18.5 kg/m2) starting a PI-based 
regimen was higher than other BMI categories, the proportion of PI and NNRTI-based first 
ART regimens was relatively uniform in the normal weight through the morbidly obese 
categories.
The percentage of NA-ACCORD participants who were overweight at ART initiation was 
relatively uniform from the period 1998–2000 to 2007–2010 (29% vs. 31%, p = 0.11), but 
the percentage of obese participants increased over this time (11% vs. 17%, p < 0.001; 
Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/
aid). The proportion of female and nonwhite participants also increased over time (p < 0.01 
for both). There was considerable variability in the first ART regimen: PI-based regimens 
predominated in 1998–2000 and NNRTI-based regimens predominated in 2007–2010.
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The estimated BMI at ART initiation increased in a roughly linear manner between 1998 
and 2010 after adjusting for differences in baseline CD4+ T cell count, age, sex, and race (p 
< 0.001; Table 2). Compared to the reference year 2003, pre-ART average BMI was lower 
in 1998 (−0.55 kg/m2; 95% CI: −0.94, −0.17) and higher in 2010 (0.83 kg/m2; 95% CI: 0.57, 
1.10). There were also significant differences in baseline BMI by race and sex. Among men, 
the BMI of nonwhites was 0.65 kg/m2 higher compared to whites, while among women this 
difference was 1.19 kg/m2. In addition, older age and a higher pretreatment CD4+ T cell 
count were associated with a higher BMI.
Median BMI in the matched NHANES participants increased from 25.0 to 26.0 kg/m2 
between 1998 and 2010, as compared to an increase from 23.8 to 24.8 kg/m2 in NA-
ACCORD over the same period. The estimated BMI increased in all gender and racial 
groups between 1998 and 2010 in NA-ACCORD, but there was more variability observed in 
NHANES (Fig. 1). In 1998, the prevalence of obesity in the NA-ACCORD participants was 
lower than in the matched NHANES participants (9% vs. 22%), but the difference in obesity 
prevalence between cohorts was less pronounced in 2010 (18% vs. 27%, data not shown).
Of NA-ACCORD participants 13,591 (96%) had a recorded weight value during the 3 years 
after starting ART. BMI and weight (kg) measurements changed in tandem after treatment 
initiation because height was treated as a fixed value. Weight gain at 1 and 3 years after 
ART initiation was significantly greater among those with a lower BMI at the start of 
treatment (Table 1). In all BMI categories, approximately 80% of the weight gain observed 
at 3 years could be attributed to the change in the first year of treatment. However, there 
were marked sex and race differences (p < 0.001 for both interaction terms). White and 
nonwhite men had a sharp early rise in weight while women showed a more uniform rise 
over 3 years (Fig. 2). A greater weight gain was also associated with a lower pretreatment 
CD4+ T cell count and higher log10 viral load (p < 0.001 for both), and those with an age of 
approximately 35 years had greater weight gain compared to younger or older individuals (p 
< 0.001, data not shown).
Weight over time since ART initiation stratified by year of ART initiation is shown in Fig. 
3. While the presence of multiple interactions between model terms complicates the 
interpretation of individual variables, we observed a significant, nonlinear relationship 
between weight change and treatment year (p < 0.001). In early cohort years (1998–2002), 
patients tended to gain weight during the first year, which then reached a plateau or fell in 
the subsequent two years. In later cohort years the weight gain continued over the full 3 
years. Data for those starting ART in 2010 were truncated at 1 year.
After 1 year of ART, 20% of participants with a normal BMI at ART initiation had become 
overweight, and 15% of those overweight at baseline had become obese (Supplementary 
Table S2). After 3 years of ART, 22% of participants with a normal BMI at ART initiation 
had become overweight, and 18% of those overweight at baseline had become obese. A 
reclassification after 3 years from normal BMI to overweight was most common among 
white males (23%), while a shift from overweight to obese was most common among 
nonwhite females (21%). In comparison, relatively few participants moved to the next lower 
BMI category after 3 years if they were overweight (16%) or obese (13%) at ART initiation.
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Lastly, we compared the BMI after 3 years of ART in the subset of NA-ACCORD 
participants who started treatment in 2006 or 2007 (i.e., we used the mean BMI of these 
individuals in 2009 or 2010) against the mean BMI of NHANES participants in the 2009–
2010 survey period matched for age and stratified by sex and race. The NHANES 
participants in our comparison group were not followed longitudinally and therefore a BMI 
value after 3 years was not available for those evaluated in 2006 or 2007; as a surrogate we 
used the BMI of age-matched participants in the 2009–2010 cohort. After 3 years of ART, 
the mean BMI of HIV-infected white men, nonwhite men, and nonwhite women was not 
significantly different from age-matched peers in the 2009–2010 NHANES data (p > 0.05 
for all). However, while HIV-infected white women appeared to gain the least weight on 
treatment, the mean BMI of HIV-infected white women after 3 years of ART (30.8 kg/m2) 
still exceeded the mean BMI of age-matched NHANES participants (27.9 kg/m2, p = 0.02).
Two sensitivity analyses excluding all women under 35 years of age and under 40 years of 
age were performed with the goal of reducing confounding due to unrecorded pregnancies 
(pregnancy status is not included in NA-ACCORD). The results for both were similar to the 
primary analysis for BMI at ART initiation, weight gain after ART initiation among both 
white and nonwhite women, and weight gain according to year of treatment initiation.
Discussion
For much of the past decade, U.S. and Canadian HIV-infected individuals in NA-ACCORD 
had lower BMI at the time of ART initiation compared to the general U.S. population of 
similar age, sex, and race. However, weight gain in the first 3 years after starting ART 
resulted in NA-ACCORD participants “catching up” to the average BMI of similarly aged 
members of the general population, and exceeding the general population in the case of 
HIV-infected white females. Further clinical studies are needed to understand how the 
overlapping metabolic, cardiovascular, and inflammatory derangements observed more 
frequently in both excess adiposity and treated HIV interact in a single individual. The 
pattern of short-term weight gain and increased obesity prevalence after ART initiation we 
observed in NA-ACCORD may have profound consequences for the future burden of 
cardiometabolic diseases and other noncommunicable diseases (NCDs) in the HIV-infected 
population.
Our findings of a high prevalence of overweight/obesity and weight gain on ART are similar 
to reports from prior single-clinic or smaller HIV cohort studies.4,5,19,20 An analysis of the 
U.S. Military HIV Natural History Cohort between 1985 and 2004 found that 37% of 
participants were overweight at the time of HIV diagnosis and 9% were obese.4 These rates 
were not constant, however, as the proportion of overweight doubled when comparing the 
period 1985–1990 to 1996–2004, and the proportion of obese was 4-fold higher. In a point-
prevalence study of HIV-infected adults in Philadelphia, obesity was most common in 
African American women (30%) and non-African American women (23%) compared to 
men (13% versus 8%, respectively).5 Similar studies have also found higher obesity rates 
among HIV-infected individuals of African origin as compared to whites, and women as 
compared to men, in the United States and in Europe.21,22
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Two recent studies report substantial weight gain after ART initiation, particularly among 
nonwhite and uninsured individuals. In South Texas, an area with a large uninsured and 
Hispanic population, 38% of patients were overweight and 22% were obese at ART 
initiation.7 Overweight/obesity was more common among nonwhites irrespective of 
insurance status, and modeling based on BMI change per year projected 30% of overweight 
patients would become obese within 4 years of treatment. Similarly, an analysis of patients 
starting ART in Alabama found that approximately 20% of normal-weight patients became 
overweight after 2 years of ART, and 20% of the overweight became obese.6 Similar trends 
were seen at 12 months in a North Carolina cohort.23
The causes underlying the progressive rise in body weight among the HIV-infected 
population are likely a complex mix of interrelated and shifting lifestyle trends in society at 
large, HIV provider and patient conceptions of health and priorities for care, changes in 
guidelines for initiating ART, and the introduction of new ART agents, among other factors. 
While recent data show a stabilization in U.S. obesity prevalence rates outside of the 
Southeast, this plateau comes at the end of a progressive three-decade climb in the 
proportion of overweight and obese persons in North America.1 The epidemic of obesity in 
the United States and Canada appears to result more from large increases in average daily 
caloric intake rather than large reductions in physical activity.24–27 It is reasonable to 
assume that HIV patients are similarly affected by factors driving obesity in the general 
population, particularly as earlier treatment and effective ART preempt the cachexia 
common in advanced untreated disease.28,29
Determining an optimal weight for HIV-infected patients is difficult due to a lack of data on 
how cardiovascular and metabolic disease risk factors interact in comorbid HIV and obesity. 
In a large Southeastern cohort there was a stepwise increase in the prevalence of 
“multimorbidity,” or the presence of multiple comorbidities involving different organ 
systems or physiologic pathways, among ART-treated patients in progressively higher BMI 
categories.8 Overweight and obese HIV-infected individuals also demonstrate progressively 
higher levels of several circulating inflammatory cytokines associated with the development 
of diabetes, cardiovascular disease, and all-cause mortality.30–34 Increasing BMI is 
associated with greater dyslipidemia and incident diabetes diagnoses in HIV patients, and 
abdominal obesity has been linked to accelerated neurocognitive decline.9,10,35
The risk of incident comorbid illnesses in HIV-infected adults may not rise in a linear 
fashion as adiposity increases. In a retrospective cohort study of 1,089 patients over the 
period 1998–2010 at a large academic HIV clinic in the Southeast, a BMI of 30 kg/m2 was 
associated with a lower risk of the combined endpoint of an incident cardiovascular, hepatic, 
renal, or oncologic disease diagnosis compared to a BMI of 25 kg/m2, but this protective 
effect was attenuated at a BMI of 35 kg/m2.36 The association persisted after adjusting for 
differences in statin and antihypertensive treatment, and self-reported tobacco, alcohol, and 
drug use. The nonlinear relationship between BMI and incident disease diagnoses may be 
due in part to differences in patient risk behaviors; an analysis of the Women’s Interagency 
HIV Study found that individuals with higher BMI were less likely to be current smokers, or 
engage in moderate to heavy alcohol intake, injection drug use, or cocaine use.37,38 Further 
clinical research is needed to understand how HIV infection and antiretroviral agents affect 
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the already complex interactions of adipose tissue, innate and cellular immune function, 
metabolism, and cardiovascular health before our current preventive care and disease 
management practices, formulated largely based on evidence from uninfected populations, 
can be effectively applied to HIV-infected individuals on long-term ART.39,40
A substantial number of NA-ACCORD cohorts do not include longitudinal BMI data and 
could not be included in our analysis, which may have reduced the power and the 
geographic representation. Our analysis was also limited by a lack of pregnancy data on 
female participants. By excluding women with more than a 10% weight change within 6 
months of ART initiation, we may have underestimated weight gain on treatment. While our 
comparator NHANES population was weighted to the age distribution of the NA-ACCORD 
participants (and matched by sex and race), there may have been geographic, 
socioeconomic, or other unrecognized confounders between the two groups; the most 
obvious would be the lack of Canadians in NHANES. The NA-ACCORD cohort also may 
not be fully reflective of the HIV epidemic in North America, particularly in regard to 
patients in remote rural areas or smaller, private infectious diseases or general medicine 
practices. The NA-ACCORD dataset does not include information on income, education, 
employment status, or dietary composition and total intake, which may have affected body 
composition at treatment initiation and weight gain on ART. Our analysis did not account 
for viral load measurements on ART, and we could not assess changes in weight according 
to virologic suppression status. Our analysis ended in 2010, which precluded an assessment 
of whether the obesity epidemic may have finally crested in both the HIV-infected and 
uninfected populations.1 Lastly, BMI and weight are imprecise measures of body 
composition, and variability in lean versus fat mass partitioning was likely present.
An enduring image of the pre-ART era was the severely wasted AIDS patient, and early in 
the epidemic weight gain was viewed as beneficial in HIV-infected individuals. In North 
America, we found that the BMI at ART initiation among HIV-infected adults increased 
between 1998 and 2010, as has weight gain. Among providers and patients, a relic of this 
earlier period may be the sense that a “healthy” (i.e., higher) weight remains desirable, 
though this view needs to be balanced against the potential health risks of excess adiposity. 
While further research is needed to understand the metabolic and cardiovascular 
consequences of comorbid HIV and obesity, the management of weight-related health 
conditions will be a priority and challenge for the care of contemporary HIV-infected 
individuals.
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Estimated mean BMI at ART initiation (and 95% confidence interval) for HIV-infected NA-
ACCORD participants and age-matched NHANES participants, stratified by sex and race. 
NA-ACCORD model adjusted for age, CD4+ T cell count at treatment initiation, and cohort. 
*NHANES data reported in 2-year intervals and weighted to match the NA-ACCORD 
cohort according to CDC guidelines. ART, antiretroviral therapy; BMI, body mass index; 
NHANES, National Health and Nutrition Examination Survey. Light gray shading 
represents females and dark gray shading represents males.
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Predicted mean weight (and 95% confidence intervals) over 3 years after ART initiation, 
stratified by sex and race in NA-ACCORD, 1998–2010. Model adjusted for age, initial 
antiretroviral regimen, year of treatment initiation, cohort, and baseline weight, CD4+ T cell 
count, and log10 HIV RNA.
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Estimated mean weight over the initial 3 years following ART initiation, stratified by year of 
treatment initiation in NA-ACCORD, 1998–2010. Model adjusted for age, sex, race, initial 
antiretroviral regimen, cohort, and baseline weight, CD4+ T cell count, and log10 HIV RNA. 
Participants starting ART in 2010 were truncated at 1 year of follow-up.
Koethe et al. Page 14





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Koethe et al. Page 16
Table 2
Relationship of Body Mass Index and Year of Antiretroviral Therapy Initiation, Adjusted for Age, CD4+ T 










Year of ART initiation
  1998 −0.55 (−0.94, −0.17) <0.001
  2000 −0.41 (−0.57, −0.25)
  2003 (reference) 0
  2005 0.32 (0.16, 0.48)
  2007 0.56 (0.37, 0.76)
  2010 0.83 (0.57, 1.10)
Age at ART initiation (years) <0.001
  25 −1.55 (−1.81, −1.29)
  30 −0.68 (−0.78, −0.58)
  35 (reference) 0
  40 0.31 (0.21, 0.41)
  45 0.32 (0.11, 0.54)
CD4 at ART initiation (cells/µl)
  100 −1.68 (−1.89, −1.47)
  200 −0.72 (−0.90, −0.54) <0.001
  350 (reference) 0
  500 0.39 (0.31, 0.47)
Sex <0.001
  In subjects of white race
    Male −2.80 (−3.30, −2.29)
    Female (reference) 0
  In subjects of non-white race
    Male −3.33 (−3.61, −3.06)
    Female (reference) 0
Race <0.001
  In men
    Nonwhite 0.65 (0.45, 0.84)
    White (reference) 0
  In women
    Nonwhite 1.19 (0.65, 1.73)
    White (reference) 0
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